Amino lipids and methods for the delivery of nucleic acids
The present invention provides superior compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target proteins at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.
1. A lipid particle comprising an amino lipid having the structure
or a salt of thereof.
2. The lipid particle of claim 1 , wherein the particle further comprises a neutral lipid and a lipid capable of reducing particle aggregation.
3. The lipid particle of claim 1 , wherein the lipid particle comprises:
(i) DLin-K-C2-DMA;
(ii) a neutral lipid selected from DSPC, POPC, DOPE, and SM;
(iii) cholesterol; and
(iv) a PEG-lipid,
in a molar ratio of about 20-60% DLin-K-C2-DMA: 5-25% neutral lipid: 25-55% Chol: 0.5-15% PEG-lipid.
4. The lipid particle of claim 1 , further comprising a therapeutic agent.
5. The lipid particle of claim 4 , wherein the therapeutic agent is a nucleic acid.
6. The lipid particle of claim 5 , wherein the nucleic acid is a plasmid.
7. The lipid particle of claim 5 , wherein the nucleic acid is an immunostimulatory oligonucleotide.
8. The lipid particle of claim 5 , wherein the nucleic acid is selected from the group consisting of: a siRNA, a microRNA, an antisense oligonucleotide, and a ribozyme.
9. The lipid particle of claim 8 , wherein the nucleic acid is a siRNA.
10. A pharmaceutical composition comprising the lipid particle of claim 4 and a pharmaceutically acceptable excipient, carrier, or diluent.
11. A method of modulating the expression of a polypeptide by a cell, comprising providing to a cell the lipid particle of claim 4 .
12. The method of claim 11 , wherein the therapeutic agent is selected from an siRNA, a microRNA, an anti sense oligonucleotide, and a plasmid capable of expressing an siRNA, a microRNA, or an antisense oligonucleotide, and wherein the siRNA, microRNA, or antisense RNA comprises a polynucleotide that specifically binds to a polynucleotide that encodes the polypeptide, or a complement thereof, such that the expression of the polypeptide is reduced.
13. The method of claim 12 , wherein the therapeutic agent is a plasmid that encodes the polypeptide or a functional variant or fragment thereof, such that expression of the polypeptide or the functional variant or fragment thereof is increased.
14. A method of treating a disease or disorder characterized by overexpression of a polypeptide in a subject, comprising providing to the subject the pharmaceutical composition of claim 10 , wherein the therapeutic agent is selected from an siRNA, a microRNA, an antisense oligonucleotide, and a plasmid capable of expressing an siRNA, a microRNA, or an antisense oligonucleotide, and wherein the siRNA, microRNA, or antisense RNA comprises a polynucleotide that specifically binds to a polynucleotide that encodes the polypeptide, or a complement thereof.
15. A method of treating a disease or disorder characterized by underexpression of a polypeptide in a subject, comprising providing to the subject the pharmaceutical composition of claim 10 , wherein the therapeutic agent is a plasmid that encodes the polypeptide or a functional variant or fragment thereof.
16. A method of inducing an immune response in a subject, comprising providing to the subject the pharmaceutical composition of claim 10 , wherein the therapeutic agent is an immunostimulatory oligonucleotide.
17. The method of claim 16 , wherein the pharmaceutical composition is provided to the patient in combination with a vaccine or antigen.
18. A vaccine comprising the lipid particle of claim 7 and an antigen associated with a disease or pathogen.
19. The lipid particle of claim 4 , wherein the therapeutic agent is mRNA.
20. The method of claim 11 , wherein the therapeutic agent is mRNA.